The government approved a flu vaccine on Wednesday that is made in a fundamentally different way than every flu shot before it. Instead of growing influenza virus in chicken eggs over roughly six months and then killing it to make a shot, Moderna’s vaccine delivers a set of genetic instructions that tell the body to build the flu protein itself — the same approach the company used for its COVID-19 vaccines. The body then learns to recognize that protein and fight the real virus.
The Food and Drug Administration approved the vaccine, called mFLUSIVA, for all adults 50 years and older. It is the first licensed flu shot in the United States made with messenger RNA technology.
The practical advantage is speed. Every year, manufacturers must guess months in advance which flu strains will circulate, then commit to a long production run. A genetic-instruction vaccine can be reformulated far faster, which means a closer match to the strains actually making people sick.
In late-stage testing, the shot was roughly 27% more effective than a standard flu vaccine. The trial enrolled 40,805 adults across 11 countries, comparing the vaccine against both standard-dose and high-dose flu shots already on the market.
For Moderna, the approval is a significant commercial win. The company called it its fourth approved product in the United States, and chief executive Stéphane Bancel described the vaccine as “an important new option for America’s seniors.” Moderna expects supply at select U.S. retailers in the coming weeks, alongside its COVID-19 and RSV vaccines for the 2026–2027 respiratory virus season.
A Reversal at the Agency
Getting here was not routine. The FDA initially refused to review Moderna’s application this year, then reversed course a week later. Agency officials said they wanted more data because Moderna had compared its vaccine against a standard flu shot in adults 65 and older, even though federal guidelines call for a high-dose vaccine in that age group. Moderna has said the FDA previously signed off on the trial design.The FDA’s independent vaccine advisory committee then voted unanimously in June to recommend approval.
Moderna also presented data in adults 65 and older comparing its shot against Fluzone High-Dose, showing stronger antibody responses at both one month and six months — the basis for how the agency handled the older age group.
That split shows up in the approval itself. Adults 50 to 64 received a traditional approval. Adults 65 and older received an accelerated approval, conditioned on Moderna running an additional clinical trial in that older group.
The Politics Around It
The approval lands in an unusually hostile policy environment for the technology. The Department of Health and Human Services canceled 22 projects worth about $500 million focused on mRNA vaccine development in August 2025, with Secretary Robert F. Kennedy Jr. asserting — against the available evidence — that such vaccines do not protect effectively against respiratory infections like COVID and flu. The agency’s former top vaccine regulator declined to review the Moderna application, and the shot is expected to draw pushback from the health secretary’s allies.
That matters for business reasons, not just political ones. Whether insurers cover the vaccine at no cost, and whether pharmacies stock it in volume, depends heavily on federal advisory recommendations — the step that comes after approval. A shot that clears the FDA but never gets a firm recommendation can end up as an out-of-pocket product that most people never encounter at the counter.
The market it enters is large. Influenza killed between 23,000 and 78,000 people in the United States during the 2025–26 season, according to CDC estimates.
What Patients Should Expect
Reported side effects include pain, tenderness and swollen lymph nodes at the injection site, along with fatigue, headache, muscle or joint pain, nausea or vomiting, and fever. Advisory panelists noted those reactions occurred at higher rates than with comparison vaccines and stressed that clear communication about the side effect profile will matter for uptake, given public skepticism toward mRNA technology.
Competitors are close behind. Pfizer has mRNA-based flu vaccines in development, and a combined COVID-and-flu shot from Moderna was approved in Europe earlier this year. Moderna’s flu vaccine is also under regulatory review in the European Union, Canada and Australia.
For older Americans this fall, the choice at the pharmacy counter will simply be a new box on the shelf. Whether it becomes the default flu shot — or a niche option for those willing to pay — will be decided in Washington, not in the lab.
JBizNews Desk | New York
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.
